Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Zilongjin tablets in non-small cell lung cancer
ChiCTR2400085550Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zilongjin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Beijing Hospital of Traditional Chinese Medicine. Primary endpoints: Survival rate at 1 year, Overall survival at 12 months and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
zilongjin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085550.